Circulating intestinal fatty acid-binding protein (I-FABP) levels in acute decompensated heart failure

Takeshi Kitai, Yong Hyun Kim, Kathryn Kiefer, Rommel Morales, Allen G. Borowski, Justin L. Grodin, W. H.Wilson Tang

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background Venous congestion has become increasingly recognized as a potential contributor to end-organ dysfunction in heart failure. Elevated I-FABP, which is excreted specifically from damaged intestinal epithelial cells, has been found in patients with abdominal hypertension and intestinal ischemia. We hypothesize that elevated intestinal fatty acid-binding protein (I-FABP) levels would identify patients with more advanced heart failure who have venous and intestinal congestion. Methods Baseline serum I-FABP levels were measured in 69 acute decompensated heart failure (ADHF) patients admitted to the intensive care unit for invasive hemodynamic monitoring and tailored medical therapy. Comprehensive echocardiography examinations were performed in all study patients, and clinical outcomes (death, cardiac transplant or left ventricular assist device placement) were assessed. Results The median circulating I-FABP level was 853 pg/ml (interquartile range: 533 to 1448 pg/ml). Age, gender, race, and baseline comorbidities were comparable between patients with low and high I-FABP levels. Although there were no significant correlations between I-FABP levels and invasively-measured hemodynamic parameters nor echocardiographic parameters, patients with higher I-FABP levels (≥ 853 g/ml) had significantly worse clinical outcomes compared to those with lower I-FABP levels (< 853 pg/ml, P = 0.025). Conclusion Circulating I-FABP levels had no association with invasively-measured hemodynamic parameters, but were associated with adverse clinical outcomes in patients with ADHF with systolic dysfunction.

Original languageEnglish (US)
Pages (from-to)491-495
Number of pages5
JournalClinical Biochemistry
Volume50
Issue number9
DOIs
StatePublished - Jun 1 2017

Fingerprint

Fatty Acid-Binding Proteins
Heart Failure
Hemodynamics
Hyperemia
Left ventricular assist devices
Systolic Heart Failure
Echocardiography
Intensive care units
Transplants
Heart-Assist Devices
Intensive Care Units
Comorbidity
Blood Proteins
Ischemia
Epithelial Cells
Hypertension
Monitoring

Keywords

  • Acute heart failure
  • Biomarker
  • Cardiorenal
  • I-FABP

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Circulating intestinal fatty acid-binding protein (I-FABP) levels in acute decompensated heart failure. / Kitai, Takeshi; Kim, Yong Hyun; Kiefer, Kathryn; Morales, Rommel; Borowski, Allen G.; Grodin, Justin L.; Tang, W. H.Wilson.

In: Clinical Biochemistry, Vol. 50, No. 9, 01.06.2017, p. 491-495.

Research output: Contribution to journalArticle

Kitai, Takeshi ; Kim, Yong Hyun ; Kiefer, Kathryn ; Morales, Rommel ; Borowski, Allen G. ; Grodin, Justin L. ; Tang, W. H.Wilson. / Circulating intestinal fatty acid-binding protein (I-FABP) levels in acute decompensated heart failure. In: Clinical Biochemistry. 2017 ; Vol. 50, No. 9. pp. 491-495.
@article{4f7734f11d234b04adb72f4f64834eb7,
title = "Circulating intestinal fatty acid-binding protein (I-FABP) levels in acute decompensated heart failure",
abstract = "Background Venous congestion has become increasingly recognized as a potential contributor to end-organ dysfunction in heart failure. Elevated I-FABP, which is excreted specifically from damaged intestinal epithelial cells, has been found in patients with abdominal hypertension and intestinal ischemia. We hypothesize that elevated intestinal fatty acid-binding protein (I-FABP) levels would identify patients with more advanced heart failure who have venous and intestinal congestion. Methods Baseline serum I-FABP levels were measured in 69 acute decompensated heart failure (ADHF) patients admitted to the intensive care unit for invasive hemodynamic monitoring and tailored medical therapy. Comprehensive echocardiography examinations were performed in all study patients, and clinical outcomes (death, cardiac transplant or left ventricular assist device placement) were assessed. Results The median circulating I-FABP level was 853 pg/ml (interquartile range: 533 to 1448 pg/ml). Age, gender, race, and baseline comorbidities were comparable between patients with low and high I-FABP levels. Although there were no significant correlations between I-FABP levels and invasively-measured hemodynamic parameters nor echocardiographic parameters, patients with higher I-FABP levels (≥ 853 g/ml) had significantly worse clinical outcomes compared to those with lower I-FABP levels (< 853 pg/ml, P = 0.025). Conclusion Circulating I-FABP levels had no association with invasively-measured hemodynamic parameters, but were associated with adverse clinical outcomes in patients with ADHF with systolic dysfunction.",
keywords = "Acute heart failure, Biomarker, Cardiorenal, I-FABP",
author = "Takeshi Kitai and Kim, {Yong Hyun} and Kathryn Kiefer and Rommel Morales and Borowski, {Allen G.} and Grodin, {Justin L.} and Tang, {W. H.Wilson}",
year = "2017",
month = "6",
day = "1",
doi = "10.1016/j.clinbiochem.2017.02.014",
language = "English (US)",
volume = "50",
pages = "491--495",
journal = "Clinical Biochemistry",
issn = "0009-9120",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Circulating intestinal fatty acid-binding protein (I-FABP) levels in acute decompensated heart failure

AU - Kitai, Takeshi

AU - Kim, Yong Hyun

AU - Kiefer, Kathryn

AU - Morales, Rommel

AU - Borowski, Allen G.

AU - Grodin, Justin L.

AU - Tang, W. H.Wilson

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Background Venous congestion has become increasingly recognized as a potential contributor to end-organ dysfunction in heart failure. Elevated I-FABP, which is excreted specifically from damaged intestinal epithelial cells, has been found in patients with abdominal hypertension and intestinal ischemia. We hypothesize that elevated intestinal fatty acid-binding protein (I-FABP) levels would identify patients with more advanced heart failure who have venous and intestinal congestion. Methods Baseline serum I-FABP levels were measured in 69 acute decompensated heart failure (ADHF) patients admitted to the intensive care unit for invasive hemodynamic monitoring and tailored medical therapy. Comprehensive echocardiography examinations were performed in all study patients, and clinical outcomes (death, cardiac transplant or left ventricular assist device placement) were assessed. Results The median circulating I-FABP level was 853 pg/ml (interquartile range: 533 to 1448 pg/ml). Age, gender, race, and baseline comorbidities were comparable between patients with low and high I-FABP levels. Although there were no significant correlations between I-FABP levels and invasively-measured hemodynamic parameters nor echocardiographic parameters, patients with higher I-FABP levels (≥ 853 g/ml) had significantly worse clinical outcomes compared to those with lower I-FABP levels (< 853 pg/ml, P = 0.025). Conclusion Circulating I-FABP levels had no association with invasively-measured hemodynamic parameters, but were associated with adverse clinical outcomes in patients with ADHF with systolic dysfunction.

AB - Background Venous congestion has become increasingly recognized as a potential contributor to end-organ dysfunction in heart failure. Elevated I-FABP, which is excreted specifically from damaged intestinal epithelial cells, has been found in patients with abdominal hypertension and intestinal ischemia. We hypothesize that elevated intestinal fatty acid-binding protein (I-FABP) levels would identify patients with more advanced heart failure who have venous and intestinal congestion. Methods Baseline serum I-FABP levels were measured in 69 acute decompensated heart failure (ADHF) patients admitted to the intensive care unit for invasive hemodynamic monitoring and tailored medical therapy. Comprehensive echocardiography examinations were performed in all study patients, and clinical outcomes (death, cardiac transplant or left ventricular assist device placement) were assessed. Results The median circulating I-FABP level was 853 pg/ml (interquartile range: 533 to 1448 pg/ml). Age, gender, race, and baseline comorbidities were comparable between patients with low and high I-FABP levels. Although there were no significant correlations between I-FABP levels and invasively-measured hemodynamic parameters nor echocardiographic parameters, patients with higher I-FABP levels (≥ 853 g/ml) had significantly worse clinical outcomes compared to those with lower I-FABP levels (< 853 pg/ml, P = 0.025). Conclusion Circulating I-FABP levels had no association with invasively-measured hemodynamic parameters, but were associated with adverse clinical outcomes in patients with ADHF with systolic dysfunction.

KW - Acute heart failure

KW - Biomarker

KW - Cardiorenal

KW - I-FABP

UR - http://www.scopus.com/inward/record.url?scp=85014276206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014276206&partnerID=8YFLogxK

U2 - 10.1016/j.clinbiochem.2017.02.014

DO - 10.1016/j.clinbiochem.2017.02.014

M3 - Article

C2 - 28232029

AN - SCOPUS:85014276206

VL - 50

SP - 491

EP - 495

JO - Clinical Biochemistry

JF - Clinical Biochemistry

SN - 0009-9120

IS - 9

ER -